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To The Immune System
m
Abstract
Human Immunodeficiency Virus type 1 (HIV - 1) has been found to be the cause of
Acquired Immune Deficiency Syndrome (AIDS). This virus caused uproar during the
1980's and started a major drug discovery race among the pharmaceutical companies. It
also proved to be a milestone in the establishment of the use of computers in rational drug
design.
Evolutionary computation is a commonly used computational approach that has
been successfully applied to a variety of fields ranging from engineering to life science.
The main reason for its effectiveness is that it is driven by the principles of evolution. A
genetic algorithm is an approach to evolutionary computation that allows random
combination of data to occur in a series of generations and enables the identification of
novel systems that might otherwise have gone undetected.
This work explores the use of genetic algorithms to generate new ligand structures
that may be effective in inhibiting HIV
- 1 Protease, one of the major drug targets in HIV.
One of the computational challenges associated with drug discovery is the conversion of
chemical and biological entities into formats that the computer can use. Chemical
structures can be represented by linear character strings called SMILES strings. SMILES
(Simplified Molecular Input Line Entry Specification) strings are taken as the genetic
representation for our approach to drug discovery, and a genetic algorithm has been
developed to generate appropriate ligands for HIV-1 protease. Based on a fitness function,
IV
the ligands are evaluated and either kept or removed from the gene pool following the
"survival of the
fittest"
pattern found in nature.
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1. Introduction
LigEvolver, the tool that produces novel ligand structures, has been implemented for
specific reasons. These intentions and the way this tool is different from previous genetic
algorithm based tools is presented in this section. The necessary background and the
problem are also described.
1. 1 Fundamental Concepts
Enzymes.
Enzymes are a specialized class of proteins that act as catalysts to increase the rate of
chemical reactions.
Inhibitor
The inhibitors are chemical compounds that serve to block enzymes from functioning.
Ligands
The substrate that is bound to by a protein is also called a ligand. These can be used as
effective inhibitors. The terms ligand and inhibitor are used interchangeably in this thesis.
Genetic Algorithm
Genetic Algorithms employ concepts of evolution to search for solutions in domain
problem spaces. The individuals in a population are made to crossover and mutate to give
rise to new individuals. Depending on the ability of individuals to satisfy a fitness function,
a pre-defined quality criterion, they are either allowed to exist or eliminated from the next
generation.
Pharmacophore
This is a common template that depicts the desired spatial arrangement of chemical
properties of a potential candidate. It is the minimal structure required for inhibition.
SMILES
This is an acronym for Simplified Molecular Input Line Entry Specification. It is a method
of representing a molecule in a linear form.
1.2 Purpose of Investigation
Inhibitor design is a major part of the drug discovery process. Structure-based drug design
has been shown to produce effective results and has led to the discovery of a number of
inhibitors. There are plenty of features that lead to the design of a reliable drug such as its
bioavailability, binding affinity and interaction specificity, among other features.
In the case of enzymes with known inhibitors, it would be worthwhile to explore the
possibility of generating ligands based on scalar properties without other added
complexities. The focus of this study is directed towards determining if new ligand
structures could be derived by using a minimal set of physiochemical properties and
comparisons with known inhibitors.
Previous studies such as those by Glen et al., (1994) and Venkatasubramanian et al., (1995)
have shown the use of evolutionary techniques for drug design. Douguet et al made use of
SMILES line notation for their program LEA (Ligand by Evolutionary Algorithm).
LigEvolver differs from the past research as it makes use of the smallest number of
constraints and genetic operators for evolving ligands. Its main objective is to see if this
limited approach can lead to powerful structures.
1.3 Problem Description
There are many undiscovered therapeutic structures that have the ability to function as
inhibitors. The goal of this study is to uncover such structures by constructing a genetic
algorithm based computer tool, LigEvolver. The task is to identify new inhibitors for the
HIV - 1 Protease enzyme and LigEvolver aides this task by evolving solutions that seem
more likely to perform the task. The level of analysis of the chemical structures has been
restricted to two dimensions because of the minimalist hypothesis.
Given a set of chemical structures in the SMILES notation, LigEvolver evolves potential
inhibitors for the target enzyme. The algorithm conserves the fittest individuals in each
generation and iterates until fairly competent candidates have been produced. Each
individual is assessed based on pharmaceutically relevant criteria.
1.4 Rationale
Discovering new drugs is an extremely tedious and expensive task. Computational
derivation of potential ligand structures would help to reduce the time and the cost of drug
development. The use of a genetic algorithm to generate candidate structures could give
rise to a variety of combinations that would enable the scientist to pursue lead compounds
that have not been identified using traditional approaches.
The intention is to develop a program using a well-characterized system of an enzyme
(HIV protease) that has been crystallized in the presence of a large number on inhibitors.
In this case, the 3D structures of the drugs and the target protein are known. Once an
approach to predicting new ligands based on existing ligands has been developed, it can be
extended to open cases, where a number of drugs have been identified, but the structure of
the target enzyme and its identity are not known.
2. Methods and Materials
2. 1 Disease and Enzyme Selection
2.1.1 HIV Genome
The HIV genome consists of three main genes, namely gag, pol and env. Gag codes for
structural proteins that form the viral core. Pol genes code for Reverse Transcriptase,
Integrase and Protease, which are three essential enzymes that play a significant role in the
formation and maturation of the virus. The env gene codes the envelope for the viral
proteins [39]. Figure 2.1.1.1 shows the HIV genome encompassing the three genes.
Figure 2.1.1.1 HIV Genome
2.1 .2 Lifecycle of HIV
Human immunodeficiency virus (HIV) is a lethal retrovirus that attacks the immune
system. This retrovirus follows a specific life - cycle to infect the host cells. The viral
activity has been outlined in fig. 2. 1 .2. 1 .
BINDING The HIV binds itself to the CD4




The virus penetrates the
membrane and enters the cell with
the help of the co-receptor
Reverse Transcriptase transcribes
the viral RNA into DNA
Integrase integrates the viral DNA
with the host cell's DNA
CLEAVING Protease cleaves the viral
polyproteins into functional
proteins and the virus exits the cell
Figure 2.1.2.1 HIV Lifecycle
2.1.3 HIV Protease
As can be seen from the lifecycle, HIV Protease is a crucial enzyme that hydrolyzes viral
polyproteins into functional protein products. These products then contribute to the
further propagate the virus. This work concentrates on identifying new ligands for HIV
Protease. The flexibility and mutability of this enzyme makes it a challenging drug design
target. HIV protease acts as a dimer with two identical polypeptide chains. It has only one
active site that is depicted in the boxed region of fig. 2.1.3.1 [40].
Figure 2.1.3.1 HIV Protease and active site
Figure 2.1.3.2 HIV Protease inhibited by
lD4Y:i
*Figure generated using DeepView
2.1.4 Conserved Region
During the transcription of RNA to DNA, Reverse Transcriptase has an error rate of
about 1 in 2000 bases. Due to this the HIV strain undergoes mutation in each generation
and the nucleotide sequence of HIV Protease changes from strain to strain. However, a
conserved region has been detected. It is the residues, Asp
- Thr - Gly, of the catalytic
triad.







'Structures have been taken fromWikipedia [38]








Figure 2.1.4.4 Catalytic triad
2.1.5 Enzymatic Reaction
The HIV protease enzyme cleaves the protein at the carbonyl group of the peptide bond.
The entire process is shown with respect to the active site (Asp
- Thr - Gly) in figure
2.1.5.1 [20]. Step 1 shows the binding of HIV
- 1 protease to a peptide substrate; step 2
demonstrates the attack of the carbonyl of the scissile amide by HIV - 1 protease activated















































Figure 2.1.5.1 HIV Protease Catalytic Mechanism
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2.2 Genetic Representation in LigEvolver
2.2.1 Chromosome Representation
"Chromosome"
is the general term used to address the genotype of the individuals in a
population. The SMILES string serves as the input to the genetic program. Its simplified
representation supplies the computer with an accurate linear representation of complicated
two dimensional structures, which can be readily manipulated during evolutionary
programming [4]. It is also a standard and universal form of representation used by
chemists all over the world [1]. These reasons make it a good choice for the depiction of
the chemical compounds and a means to represent the chromosome for the genetic
program. The mapping of the chemical compound from its 3D structure to the SMILES







Figure 2.2.1.1 Transformation from 3D structure to SMILES string
2.2.2 Sample SMILES string and 2D structure of ligand
An example of the ligand structure is shown below along with the SMILES string. The















Figure 2.2.2.2 TPV Structure
2.2.3 Pharmacophoric Features Considered
For each of the ligand structures the following are the important features considered to
form the basic pharmacophore template. These features are thought to be important
interaction points between the enzyme and the ligand.
1 . Aromatic Rings [Ar]
2. Hydrogen Bond Acceptors [A]
3. Hydrogen Bond Acceptors and Donors [A/D]
4. Hydrophobic center [F]
Figure 2.2.3.1 shows how the pharmacophoric features of ligand TPV are decomposed.
14
A O
Figure 2.2.3.1 TPV Structure with labeled pharmacophoric features
Key
Hydrophobic Center
A Hydrogen Bond Acceptor
A/D Hydrogen Bond Acceptor/Donor
Ar - Aromatic Ring
2.3 Input
Before beginning the genetic algorithm, certain pre
-
processing steps had to be completed
for the construction of the input files. SMILES databases, consisting of various chemical
compounds represented as SMILES strings, were assembled. The data for these databases




Kyoto Encyclopedia of Genes and Genomes (KEGG)
ChemPDB
ChemBank
Macromolecular Structure Database (MSD)
Anti - HIV National Cancer Institute (NCI)
Protein Data Bank (PDB)
Table 2.3.1 List ofDatabases
The above mentioned databases have been downloaded from Ligand.Info which is a
collection of various small-molecule databases [27].
2.3.1 XML/Perl Parser
An XML parser was constructed to elucidate the data from the databases and to produce the
output in a format easily transferable to the database. In other words, the files from the
public databases contain information regarding a ligand such as its molecular weight,
geometrical coordinates, etc. The parser scans the dump files for the token
"SMILES"
and
extracts only the SMILES strings
for the compilation of the various input files. The lava
Parser works the same way. Depending on the type of input data file either of the parsers is
used.
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2.3.2 Protein Data Bank
A HIV database was constructed using the ligand data of the various HIV
- 1 Protease
inhibitors. These data were extracted from the Protein Data Bank (PDB) and had to be
compiled manually since the dump files from the PDB did not contain SMILES string














Figure 2.3.1 Input Construction
2.4 Output
Two files are produced as a result of running LigEvolver. One gives the details regarding
the number of children produced, maximum, minimum and average fitness for each
generation. The other file gives the final set of SMILES strings along with the generation
that it was produced.
17
2.5 External Packages
Certain calculations required the use of PerlMol, an external package comprised of
modules for performing basic computational chemistry related functions. This is freely
distributed software and a detailed description of PerlMol can be found at
(www.perlmol.org). PerlMol provided the following functionalities to LigEvolver:
1 . Calculation ofChemical formula from the SMILES string
2. Calculation of bonds from the SMILES string
3. Polar Surface Area (PSA)
A perl script was written to combine the PSA script (available at
http://www.perlmol.org/examples/polar_surface_area/) with the chemical formula and bond
calculation.
2.6 Design of LigEvolver
This section gives a detailed description of the individual components of LigEvolver. Each













Van der Waals Volume
Motif Finder
Figure 2.6.1 Components of LigEvolver
2.6.1 Genetic Algorithm
A genetic algorithm (GA) is used to evolve the population in a random manner to
generate reasonably good individuals. It is driven by the concept ofDarwinian evolution.
The use of genetic algorithms in the generation of ligands has been successfully explored
[3,4,5]. The main parts of the algorithm fall into two broad categories namely, Genetic
operators and Fitness function, which will be discussed in the following sections. The
genetic algorithm is the main module. It comprises of functions to initialize the













Add to gene pool Discard from gene pool
DecrementMatings
Figure 2.6.1.1 Flow chart ofGA
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The initial population is seeded in different styles. The ways of initialization are as follows:
1 . Initialize with known HIV inhibitors
2. Initialize with random inhibitors
3. Initialize with a mixture of known and random inhibitors
For each generation, the population is rearranged according to the fitness function and
only a fixed number of individuals is retained to contribute towards evolution while the
rest are discarded.
2.6.1.1 Genetic Operators
The genetic operators are the mechanisms through which the individuals in a population
are manipulated and changed. If evolution were viewed as a reaction, then genetic
operators can be considered catalysts. Two dominant operators observed in many
applications are the Crossover and Mutation operator. Depending on the need of the
problem customized operators may also be included as is the case in this study. The
operators used in LigEvolver are, GenFrag, Crossover and Mutator.
2.6.1.1.1 GenFrag
The functionality of this operator is to divide the input SMILES string into meaningful
fragments. This operator was introduced because random segmentation of the SMILES
string may give rise to chemically impossible or
meaningless individuals. The numbers in




Fragments after application ofGenFrag
The SMILES string is initially cut into fragments.
< > <
CC(C)CN(CC(0)C(Cclcccccl) NC(=0)OC2CCOC2) (=0)c3ccc(N)cc3
< > < ?
A random point of concatenation is chosen to give rise to two strings to serve as head and
tail. In this case the concatenation point is taken to be two. So the start of the fragment is
combined with the second fragment for the head and the rest of the fragments are
combined together to form the tail.
Fragment One (Serves as the head for the Crossover operator)
CC(C)CN(CC(0)C(Cclcccccl) NC(=0)OC2CCOC2)
Fragment Two (Serves as the tail for the Crossover operator)
(=0)c3ccc(N)cc3
Figure 2.6.1.1.1.1 Example ofGenFrag
Overlap and duplicity checks are performed within the GenFrag, to avoid redundancy in




The crossover operator is used to mate the parents. The GenFrag operator returns two
fragments that are the head and tail of an individual. Crossovers take place 90% of the time.














CC(C)C(N)CN(CC(0)C(Cc1 ccccd )) C2=C(0)C3=C(CCCCCC3)OC2
Child 2
CCC(dccccd) NC(=0)OC2CCOC2)
Figure 2.6. 1 . 1 .2. 1 Example of Crossover
2.6.1.1.3Mutator
Mutations have played an important role in the evolution of living organisms. These
operators cause variations in the gene pool. They can be both beneficial and harmful,
although harmful ones tend to be eliminated by the fitness function. A lack of mutation
23
leads to no adaptability in the population whereas levels of mutations that are too high lead







{no adaptability) (genetic breakdown)
Figure 2.6.1.1.3 Mutation rates and genetic adaptability [5]
In LigEvolver, mutations take place 10% of the time.
2.6.1.1.3.1 Amino Acid Insertion
Random places of insertion are chosen and an amino acid is included. The choice of the
amino acid is also done randomly.
24


















Tryptophan NC(Cc 1 cc2ccccc2[nH] 1 )C(=0)0
Tyrosine NC(Cc 1ccc(0)cc 1 )C(=0)0
Valine CC(C)C(N)C(=0)0
Table 2.6.1.1.3.1 Amino Acids and their SMILES string
25
2.6.1.2 Parent Selection
Parent selection is another important design factor for a genetic algorithm. There are
various selection algorithms and the one employed in this study is tournament selection. In
this method two groups of four individuals are selected randomly. The one with the highest
fitness score is selected from each group. These two individuals then serve as the parents.
In case of a tie with respect to fitness score, the parent is chosen randomly. This selection
approach follows the concept of a tournament with teams competing to get selected. Finally
the fitness score is the determinant of the winners.
Finalist One Finalist Two
Individual One Individual Three Individual Four
Figure 2.6.1.2.1 Tournament Selection
26
2.6.2 Pharmacophore Elucidator
This module is used to extract the pharmacophore from a SMILES string. The
pharmacophoric features include aromatic rings, hydrogen bond acceptor, hydrogen bond
acceptors/donors, hydrophobic regions, positive charge centers and negative charge centers.
2.6.2.1 Aromatic Rings
Aromatic rings are a circular arrangement of atoms that can be represented with alternating
single and double - bonds. It is a conjugated system of lone pairs, unsaturated bonds and
empty orbitals that put together form a strong stabilization [36]. In chemical terms,
aromatic rings contain (4n+2)II electrons, where n is an integer.
The following are the chemical compounds that would be detected by the tool as aromatic
rings.
o
Figure 2.6.2. 1 . 1 Aromatic Structure I
- A Benzene ring*
*




2.6.2.2 Hydrogen Bond Acceptor
Hydrogen atoms that are bound to electronegative atoms such as oxygen or nitrogen can
interact with lone pairs to form additional bonding [39]. The lone pairs that interact with
the hydrogen atom are termed as hydrogen bond acceptors.
The following are the chemical compounds that would be detected by the tool as hydrogen
bond acceptors.
Figure 2.6.2.2.1 Hydrogen Bond Acceptor Structure I
= 0
Figure 2.6.2.2.2 Hydrogen Bond Acceptor Structure II
O
Figure 2.6.2.2.3 Hydrogen Bond Acceptor Structure III
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N
Figure 2.6.2.2.4 Hydrogen Bond Acceptor Structure IV
2.6.2.3 Hydrogen Bond Acceptor/Donor
A group that can either accept or donate hydrogen bonds is identified as hydrogen bond
acceptor/donor.
The following are the chemical compounds that would be detected by the tool as hydrogen
bond acceptors/donor. This is not an exhaustive list, but contains a few of the common
bonds that occur in HIV inhibitors.
-OH
Figure 2.6.2.3.1 Hydrogen bond A/D Structure I
-NH-
Figure 2.6.2.3.2 Hydrogen bond A/D Structure II
29
-NH2
Figure 2.6.2.3.3 Hydrogen bond A/D Structure III
2.6.2.4 Hydrophobic Regions
The regions that repel water are termed hydrophobic regions.



















Figure 2.6.2.4.4 Hydrophobic Structure TV*
c






Figure 2.6.2.4.6 Hydrophobic Structure VI*
A
O
Figure 2.6.2.4.6 Hydrophobic Structure VII*
*
Drawings have been generated using Smi2Depict developed by University ofCalifornia,
Irvine [44]
2.6.3 MolecularWeight Calculator
As the name indicates, the molecular weight calculator computes the molecular weight
given the chemical formula. The molecular weight values (round - off weight) used by the
tool is shown in the table below.















Table 2.6.3.1 Molecular weights
2.6.4 Van DerWaals Volume
Van derWaals surfaces define the closest contact that atoms in amolecule could make with
one another. Hence it acts as an indicator of atom packing in a molecular structure. It also
has an important role in establishing the specificity of interactions
between protein binding
pockets and ligands [36].
Zhao et al have described a method for the calculation of van derWaals volume using
the
formula, V(vdW) = summation operator all atom contributions 5.92N(B) 14.7R(A)
3.8R(NR) (N(B) is the number of bonds, R(A) is the number
of aromatic rings, and R(NA)
is the number of nonaromatic rings).
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Table 2.6.4.1 Atoms and their Volumes
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2.6.5 Polar Surface Area
Polar Surface Area (PSA) is a descriptor used to indicate the bioavailability of drugs. The
surface belonging to polar atoms correlates with the transport of molecules through
membranes. Ertl et al proposed an approach for the calculation of PSA based on the
summation of surface contributions of polar fragments. PerlMol uses this method and
provides a perl script to calculate the PSA.
2.6.6 Motif Finder
The motif finder is responsible for observing common patterns between a set of strings. It is
used to derive structural similarities between compounds through the longest common
substring present in their SMILES string.
The structures of the various FDA (U.S. Food and Drug Administration) approved drugs
for HIV protease were compiled in the form of SMILES strings. These were then matched
with the recently generated ligands to determine if they have a common substring of length
greater than 9. Table 2.5.6.1 is the list of drugs that has been taken into consideration.
Brand Name Generic Name Manufacturer Name
Agenerase Amprenavir GlaxoSmithKline
Aptivus Tipranavir Boehringer Ingelheim
Crixivan indinavir, IDV, MK-639 Merck
Fortovase Saquinavir Hoffmann-La Roche
Invirase Saquinavir mesylate, SQV Hoffmann-La Roche
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Kaletra lopinavir and ritonavir Abbott Laboratories
Lexiva Fosamprenavir Calcium GlaxoSmithKline
Norvir ritonavir, ABT-538 Abbott Laboratories
Reyataz Atazanavir sulfate Bristol-Myers Squibb
Viracept nelfinavir mesylate, NFV Agouron Pharmaceuticals
Table 2.6.6.1 FDA - Approved Protease Inhibitors*
*Data taken from FDA site [42]
2.6.7 Fitness Computor
The fitness function is used to evaluate the strength and robustness of an individual element
in the population. The fitness is calculated for every entity and it determines if the
individual needs to be retained or eliminated. In a way, the fitness function biases the path
of evolution. The following is the fitness function.
F = Ar + Hd + Ha + Hy + Mw + Ps + Vd + Sm
Where,
Ar - Aromatic Ring Count Score
Hd - Hydrogen Bond Donor Score
Ha - Hydrogen Bond Acceptor Score
Hy
- Hydrophobic Region Count Score
Mw - MolecularWeight Score
Ps - Polar Surface Area Score
Vd - Van DerWaals Volume Score
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Sm - Structural Motif Score
For each of the above mentioned features scores were assigned according to their
resemblance to the existing known inhibitors with the lowest score being the minimum
matching score and the highest being the maximum match. If there are no matches to the
known inhibitor feature count then no points are assigned. A list of the known existing
inhibitors was made and their feature pattern was analyzed manually to obtain the scoring
scheme. This list has been included as appendix II.
2.6.7.1 Aromatic Ring Count
The Aromatic ring is one of the pharmacophoric features that are vital components in
determining the way the inhibitors interact with the enzyme. Table 2.6.7.1.1 gives the
scoring scheme for the aromatic ring count.
Aromatic Ring Count Score
>4 and <7 1
>1 and <4 2
= = 4 3
Table 2.6.7.1.1 Aromatic Ring Count Scoring Scheme
2.6.7.2 Hydrogen Bond Donor Count
A count of the hydrogen bond donors is taken and scores are assigned according to table
2.6.7.2.1.
37
Hydrogen Bond Donor Count Score
>1 and <5 1
>7 2
>4 and <8 3
Table 2.6.7.2.1 Hydrogen Bond Donor Count Scoring Scheme
2.6.7.3 Hydrogen Bond Acceptor Count
A count of the hydrogen bond acceptors is taken and scores are assigned according to table
2.6.7.3.1.
Hydrogen Bond Acceptor Count Score
>1 and <5 1
>7 2
>4 and <8 3
Table 2.6.7.3.1 Hydrogen Bond Acceptors Count Scoring Scheme
2.6.7.4 Hydrophobic Region Count







>4 and <8 3
Table 2.6.7.4.1 Hydrophobic Regions Count Scoring Scheme
2.6.7.5MolecularWeight
Scores are assigned according to the range of molecular weights for each compound. The
range and their corresponding score are summarized in table 2.6.7.5.1.
MolecularWeight (Daltons) Score
<500 1
>600 and <806 2
>500 and <600 3
Table 2.6.7.5.1 Molecular Weight Scoring Scheme
2.6.7.6 Polar Surface Area
The ideal polar surface range has been taken from the list of known inhibitors and scores
are attributed to a newly generated individual if its polar surface area falls within the range.
The details regarding the range and the scores are given in table 2.6.7.6.1.




Table 2.6.7.6.1 Polar Surface Area Scoring Scheme
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2.6.7.7 Van DerWaals Volume
Van der waals volume is another descriptor that is used to assign scores to the population
units. The volume range and the respective score have been shown in table 2.6.7.7.1.
Van DerWaals Volume (Angstroms3) Score
>400 and <750 1
>800 and <900 2
>900 and <1000 3
Table 2.6.7.7.1 Van DerWaals Volume Scoring Scheme
2.6.7.8 StructuralMotif
The structures of the government approved drugs were compared to the new ligand to see if
they include similarities. The presence of a significant resemblance gives a score of one
and the absence a score of zero.
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3. Results
LigEvolver was run using the data from various public databases. The results obtained
are discussed in this section. Unless otherwise specified the entire chemical figures have
been generated using CS ChemDraw Pro.
3. 1 Simulation I
The inhibitor generation was done using the parameters shown in table 3.1.1.
Property Value
Database ChemPDB
Initial Population Size 4009
Number ofMatings per Generation 150
Number ofGenerations 100
Population size per Generation 500
Table 3.1.1 Simulation I Properties
3.1.1 Significant Results









Figure 3.1.1.1.1.1 Simulation I - Generation 100 - Compound I*







Elements underlined, either in the original SMILES string or in the reconstructed string,
signify the portion of the SMILES string that is modified. This convention is followed
throughout the remaining sections.




Figure 3.1.1.1.1.2 Simulation I
- Generation 100 - Compound
n*
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COC(=0)C(Cc 1ccccc 1 )CCC 1=C(C)C(=0)NC 1C(0)CN(CCC4CCC50COC5C4)C(=0)
CCN6C(=0)c7ccccc7C6




CC(C)C(NC(C)=0)C(=0)NC(Cc 1ccccc 1 )C(0)CN(CCC4CCC50COC5C4)C(=0)CCN6
C(=0)c7ccccc7C6





Initial Population Size 10005
Number ofMatings per Generation 100
Number ofGenerations 45
Population size per Generation 500
Table 3.2.1 Simulation II Properties
3.2.1 Significant Results








Figure 3.2.1.1.1.1 Simulation II


















Figure 3.2.1.1.3.1 Simulation II
- Generation 40 - Compound IIP





CC(C)(C)NC(=0)C 1CN(CCN 1 )COC(=0)CC(0)(CCC(C)(C)0)C(=0)OC 1C2c3cc40C
Oc4cc3CCN5CCCC25C=C 1










Figure 3.2.1.2.1.1 Simulation II







Initial Population Size 6433
Number ofMatings per Generation 100
Number ofGenerations 100
Population size per Generation 500
Table 3.3.1 Simulationm Properties
3.3.1 Significant Results






CN(C)C(C 1CCNC 1C(=0)Oc 1 ccccc 1 )C(=0)N2CCCC2C(=0)NC3C(Oc4ccc(C=CNC(=
0)C(Cc5ccccc5)NC3
Reconstruction
CN(C)C(C 1CCNC 1C(=0)0c 1 ccccc 1 )C(=0)N2CCCC2C(=0)NC3COcccc(C=CNC(=0)
C(Cc5ccccc5)NC3c4))
^^
Figure 3.3.1.1.1.1 Simulation HI
- Generation 100 - Compound I (a)*
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Reconstruction
CN(C)C(C1CCNC 1C(=0)Oc 1 ccccc 1 )C(=0)N2CCCC2C(=0)NC3C(Oc4ccc(C=CNC(=
0)C(Cc5ccccc5)N)C34)
Figure 3.3.1.1.1.2 Simulation III - Generation 100





Figure 3.3.1.1.1.3 Simulation HI - Generation 100 - Compound I (c)*
*"









Figure 3.3.1.1.2.1 Simulation III - Generation 100







Figure 3.3.1.1.2.2 Simulation III - Generation 100 - Compound II (b)*











Initial Population Size 2344
Number ofMatings per Generation 100
Number of Generations 100
Population size per Generation 300
Table 3.4.1 Simulation IV Properties
3.4.1 Significant Results






NC(=0)C2CCCCN2C(=0)C(Cc3ccccc3)NC(=0)C(Cc4ccccc4)NC 1 CN1CCN(CC 1 )CC(
C)ClNC(=0)C(Cc2)
Reconstruction
NC(=0)C2CCCCN2C(=0)C(Cc3ccccc3)NC(=0)C(Cc4ccccc4)NC 1 CN1CCN(CC 1 )CC(
C)C1NC(=0)C(C)




CN1CCN(CC 1 )CC(C)C 1NC(=0)C(Cc2ccccc2)NC(=0)C(CCCCCC(=0)NO)NC(=0)C3
CCCN3Clc5ccccc35
Reconstruction
CN 1CCN(CC 1 )CC(C)C 1NC(=0)C(Cc2ccccc2)NC(=0)C(CCCCCC(=0)NO)NC(=0)C3
CCCN3Clc5ccccc5





Initial Population Size 71
Number ofMatings per Generation 100
Number of Generations 100
Population size per Generation 150
Table 3.5.1 Simulation V Properties
3.5.1 Significant Results












Figure 3.5.1.1.1.1 Simulation V





CC1CCC(0)C 1CC(C)(C)NC(=0)C 1CC2CCCCC2CN 1C(0)C(0)C(OCc4ccccc4)C(=0)
NCc5c(F)cccc5











Figure 3.5.1.3.1.1 Simulation V - Generation 9 - Compound I*





Initial Population Size 42689
Number ofMatings per Generation 100
Number ofGenerations 200
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Population size per Generation 1000










Figure 3.6.1.1.1.1 Simulation VI
- Generation 199 - Compound I
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3.7 Fitness Behavior
It was noted that the fitness steadily increased with the number of generations. After a
certain number of generations the fitness values approached an upper limit and this value
remained constant through the subsequent generations. Figure 3.7.1 shows the fitness
behavior chart across two simulations.
Average Fitness
Figure 3.7.1 Fitness behavior
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4. Discussion
The approach used in this study does not take into account the entire complexities involved
in ligand design. It is limited due to the non - incorporation of the 3D features. The main
objective of this research was to investigate if scalar properties such as those used in the
fitness function would derive promising ligand structures. Another aspect was to
experiment with the application of genetic algorithms to the domain of ligand generation.
From the results it can be inferred that the tool generated ligands that were hopeful and
novel by nature. It also proved that genetic algorithm is an efficient computational
approach towards solving problems of this nature. Certain compounds that were produced
by LigEvolver had striking similarities to existing known inhibitors. A few of those are
presented here.
Figure 4. 1 LigEvolver Compound P
67
(a) 1NPW (b) 1C6S
-CO
(c) 1W5X




















Figure 4.4 Similarities of compound II with known inhibitor 1D4K [43]
Figure 4.5 LigEvolver Compound IIP
69
?-,
(a) 2A4F (b) 1HWR
Figure 4.6 Similarities of compound III to known inhibitors [43]
A few compounds were generated that had a totally new structure than the ones already
proved to be inhibitors. One such compound from this class of result is shown in Figure
4.7.
Figure 4.7 LigEvolver Compound
IV*
*Drawings generated using CS ChemDraw Pro.
Table 4.1 shows the various input database for the corresponding compounds.
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LigEvolver Compound # Input Database




Table 4. 1 LigEvolver compounds with corresponding input databases
71
5. Conclusion
LigEvolver succeeded in generating new ligands using the minimalist approach. The results
have been promising, but given the nature of the problem there is no computational way of
verifying the solutions. A worthwhile future enhancement would be to improvise the fitness
function by incorporating the 3D properties. Despite some unresolved issues, this tool
provides an extensible first step towards generation of inhibitors that possess the potential
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1. Non - hydrogen atoms are specified by their atomic symbol enclosed in square
brackets. The second letter of the two - letter symbol must be entered in lower
case.
2. Elements in the "organic subset", B, C, N, O, P, S, F, CI, Br and I, may be written
without brackets if the number of attached hydrogens conforms to the lowest
normal valence consistent with explicit bonds.
3. Elements not in the organic subset must be described in brackets.
4. Attached hydrogens and formal charges are always specified inside brackets. The
number of attached hydrogens is shown by the symbol H followed by an optional
digit (e.g., [NH4+] - ammonium cation).
5. Similarly, a formal charge is shown by one of the symbols + or -, followed by an
optional digit (e.g., [Fe+2] - iron (II) cation). The form [Fe+++] is considered
synonymous with the form [Fe+3].
6. If unspecified, the number of attached hydrogens and charges is assumed to be
zero for an atom inside the bracket.
7. Atoms in aromatic rings are specified by lower case letters; e.g., normal carbon is
represented by the letter C, aromatic carbon by c.
8. Single bond is represented by the symbol
-
9. Double bond is represented by the symbol =
10. Triple bond is represented by the symbol #
1 1 . Aromatic bonds are represented by :
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12. Single and aromatic bonds may be, and usually are, omitted.



















H3C CH C OH
SMILES
CC(C)C(=0)0
15. Branches can be nested or stacked
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16. Cyclic structures are represented by breaking one single (or aromatic) bond in
each ring.
17. The bonds are numbered in any order.
18. Ring opening or ring closure bonds are followed by a digit immediately following













19. There are usually many different but equally valid descriptions of the same
structure


















































































24. The rule used in the SMILES system is to eliminate all hydrogen atoms except in
the following three cases:
83
1) Hydrogens connected to other hydrogens
2) Hydrogens connected to zero or more than one other atom
3) In isomeric SMILES, isotopic hydrogen specifications, eg., [2H]
In these cases, hydrogens are retained and are treated like any other atom except that
their hydrogen count is always zero.
25. Aromatic nitrogen symbol is
'n'







D.Weininger, SMILES, a Chemical Language and Information System. 1. Introduction to
Methodology and Encoding Rules, J. Chem. Inf. Comput. Sci. 1988, 28, 31-36.
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Appendix II









































































































































































































































































































































































HEXANEDIOIC ACID BENZYLAMIDE (2-

























TERT-BUTYLOXYCARBONYL GROUP H C
o
H3C
CH.
O
1HII
SOz
SULFATE ION
ACETYL-NH-VAL-CYCLOHEXYL-
CH2 [NCH2CHOH]CH2-BENZYL-VAL-NH-
ACETYL
1S6G SODIUM ION
h,c
n,c ^hh
Na+
GLYCEROL
CHLORIDE ION
CI
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ACETIC ACID
0
II
LI
HO^
^CH3
Oj. 0
CO 0
(3R,3AS,6AR)-HEXAHYDROFURO[2,3-
B]FURAN-3-YL(lS,2R)-3-[[(4-
AMINOPHENYL)SULFONYL](ISOBUTYL)
AMIN0]-l-BENZYL-2-
HYDROXYPROPYLCARBAMATE
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